Stemline Therapeutics Inc (NASDAQ:STML) has earned an average rating of “Buy” from the eight brokerages that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $32.25.

Several research firms recently weighed in on STML. HC Wainwright set a $34.00 target price on shares of Stemline Therapeutics and gave the company a “buy” rating in a research note on Monday, March 20th. Wedbush increased their target price on shares of Stemline Therapeutics from $33.00 to $40.00 and gave the company an “outperform” rating in a research note on Thursday, May 11th. Cowen and Company reiterated a “buy” rating on shares of Stemline Therapeutics in a research note on Friday, May 12th. Ladenburg Thalmann Financial Services set a $41.00 target price on shares of Stemline Therapeutics and gave the company a “buy” rating in a research note on Monday, March 20th. Finally, ValuEngine cut shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 31st.

Shares of Stemline Therapeutics (STML) remained flat at $7.65 during mid-day trading on Friday. 34,271 shares of the stock were exchanged. The stock’s market capitalization is $178.83 million. The firm has a 50-day moving average price of $8.30 and a 200-day moving average price of $9.50. Stemline Therapeutics has a 52-week low of $5.50 and a 52-week high of $14.60.

Stemline Therapeutics (NASDAQ:STML) last released its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.67) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.45) by $0.22. Stemline Therapeutics had a negative net margin of 4,058.44% and a negative return on equity of 50.06%. The company had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.30 million. On average, analysts anticipate that Stemline Therapeutics will post ($2.26) earnings per share for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Ladenburg Thalmann Financial Services Inc. raised its position in Stemline Therapeutics by 810.6% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,694 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 11,300 shares during the period. Renaissance Technologies LLC raised its position in Stemline Therapeutics by 7.9% in the fourth quarter. Renaissance Technologies LLC now owns 65,500 shares of the biopharmaceutical company’s stock valued at $701,000 after buying an additional 4,800 shares during the period. Candriam Luxembourg S.C.A. acquired a new position in Stemline Therapeutics during the third quarter valued at about $2,783,000. State Street Corp raised its position in Stemline Therapeutics by 9.2% in the fourth quarter. State Street Corp now owns 251,804 shares of the biopharmaceutical company’s stock valued at $2,694,000 after buying an additional 21,296 shares during the period. Finally, Cowen Group Inc. acquired a new position in Stemline Therapeutics during the first quarter valued at about $657,000. 37.76% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was first reported by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/06/09/stemline-therapeutics-inc-stml-receives-consensus-recommendation-of-buy-from-brokerages.html.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Receive News & Ratings for Stemline Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.